HOME >> BIOLOGY >> NEWS
ESC Congress 2005 to utilise studies, sessions and sunshine to shed light on women and CVD

Sophia Antipolis, France, 21 June 2005: With the aim of better understanding and addressing women and cardiovascular disease (CVD), the European Society of Cardiology (ESC) has made women and CVD the focus of its next major annual event, the ESC Congress, which will take place in Stockholm, 3 7 September 2005.

The ESC Congress will highlight women and CVD by revealing results from the ESC Policy Conference and the ESC Euro Heart Survey during specific sessions at the Congress. The ESC also will provide information with regard to women and CVD during a two-day outdoor public event that will run alongside the ESC Congress, entitled 'For Your Heart's Sake,' 2 3 September 2005 in central Stockholm.

In preparation for the ESC Congress' focus, the ESC is convening a Policy Conference on 'CVD in Women' on 23 24 June 2005, which will bring together approximately 60 cardiologists and experts from the 49 ESC member countries to review and discuss medical literature on CVD in women. The group will evaluate the gap between scientific data and the perception about the role of CVD risk factors in women's health. Strategies will be discussed to promote research in the field of CVD in women and to educate both cardiologists and their patients. The results of this conference will be released during the ESC Congress 2005, and also through an article to be published in the European Heart Journal, an official journal of the ESC.

The ESC Congress' selection of sessions on women and CVD will include release of the Euro Heart Survey database analyses with incidence and treatment trends of women with CVD across Europe. Analyses of the Euro Heart Survey databases are expected to greatly contribute to an increased understanding and treatment of women and CVD through insight into manifestation, treatment and co-morbidity patterns in women compared to men.

There will also be a special focus on women and CVD, including specific information on risk factor reduc
'"/>

Contact: Gina Dellios
gdellios@escardio.org
33-492-948-627
European Society of Cardiology
21-Jun-2005


Page: 1 2 3

Related biology news :

1. AAAS analysis finds Congress would add billions to FY 2008 R&D investment
2. 2nd International EuroFIR Congress
3. Prize winners announced at ISNs World Congress of Nephrology
4. Nanotechnologys past, present and future: A Congressional perspective
5. Press registration -- World Congress of Nephrology, April 21-25, 2007, Rio de Janeiro, Brazil
6. Minister Lunn to speak at 10th National Forest Congress
7. Conservationist and actor Harrison Ford honored by Congressional Foundation
8. Q&A with Jeffrey Sachs on July 10 at Soils Congress
9. 18th World Congress of Soil Science
10. PITTs McGowan Institute for Regenerative Medicine presenting new research at World Congress
11. International Society of Nephrologys World Congress of Nephrology 2007

Post Your Comments:
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... awarded the 44th Rosenstiel Award for Distinguished Work in ... exploring the mechanisms of genomic instability and its implications ... the second alumnus to win the Rosenstiel Award; the ... , Alt is the Charles A. Janeway Professor of ... and an investigator at the Howard Hughes Medical Institute ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
(Date:10/22/2014)... October 21, 2014 The North American ... market North America with analysis and forecast of revenue. ... and is expected to reach $623.6 million by 2018, ... , Browse through the TOC of the North American ... the in-depth analysis provided. This also provides a glimpse ...
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
Cached News: